Literature DB >> 28306519

Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs.

Jenna Khan1, Joshua A Lieberman1, Christina M Lockwood1.   

Abstract

microRNAs (miRNAs) hold promise as biomarkers for a variety of disease processes and for determining cell differentiation. These short RNA species are robust, survive harsh treatment and storage conditions and may be extracted from blood and tissue. Pre-analytical variables are critical confounders in the analysis of miRNAs: we elucidate these and identify best practices for minimizing sample variation in blood and tissue specimens. Pre-analytical variables addressed include patient-intrinsic variation, time and temperature from sample collection to storage or processing, processing methods, contamination by cells and blood components, RNA extraction method, normalization, and storage time/conditions. For circulating miRNAs, hemolysis and blood cell contamination significantly affect profiles; samples should be processed within 2 h of collection; ethylene diamine tetraacetic acid (EDTA) is preferred while heparin should be avoided; samples should be "double spun" or filtered; room temperature or 4 °C storage for up to 24 h is preferred; miRNAs are stable for at least 1 year at -20 °C or -80 °C. For tissue-based analysis, warm ischemic time should be <1 h; cold ischemic time (4 °C) <24 h; common fixative used for all specimens; formalin fix up to 72 h prior to processing; enrich for cells of interest; validate candidate biomarkers with in situ visualization. Most importantly, all specimen types should have standard and common workflows with careful documentation of relevant pre-analytical variables.

Entities:  

Keywords:  FFPE; biomarker; circulating; miRNA; pre-analytical; standardization; tissue; variables

Mesh:

Substances:

Year:  2017        PMID: 28306519     DOI: 10.1515/cclm-2016-0471

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  16 in total

Review 1.  MicroRNAs as biomarkers for clinical studies.

Authors:  Igor P Pogribny
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-15

Review 2.  Sox6, A Potential Target for MicroRNAs in Cardiometabolic Disease.

Authors:  Mohammad Saleem; Sharla Rahman; Fernando Elijovich; Cheryl L Laffer; Lale A Ertuglu; Sepiso K Masenga; Annet Kirabo
Journal:  Curr Hypertens Rep       Date:  2022-02-05       Impact factor: 5.369

3.  High Clinical Impact of Broad-Range Fungal PCR in Suspected Fungal Sinusitis.

Authors:  Andrew Bryan; James A Mays; Joshua A Lieberman; Karen Stephens; Kyoko Kurosawa; Patrick C Mathias; Dhruba SenGupta; Lori Bourassa; Stephen J Salipante; Brad T Cookson
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

4.  Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.

Authors:  Vlastimil Kulda; Martin Svaton; Petr Mukensnabl; Kristyna Hrda; Pavel Dvorak; Zbynek Houdek; Katerina Houfkova; Radana Vrzakova; Vaclav Babuska; Milos Pesek; Martin Pesta
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

Review 5.  Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers.

Authors:  Perry V Halushka; Andrew J Goodwin; Marc K Halushka
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

6.  Diagnostic Performance of a Panel of miRNAs (OsteomiR) for Osteoporosis in a Cohort of Postmenopausal Women.

Authors:  K Kerschan-Schindl; M Hackl; E Boschitsch; U Föger-Samwald; O Nägele; S Skalicky; M Weigl; J Grillari; P Pietschmann
Journal:  Calcif Tissue Int       Date:  2021-01-11       Impact factor: 4.333

7.  Methodological considerations for measuring biofluid-based microRNA biomarkers.

Authors:  Brian N Chorley; Elnaz Atabakhsh; Graeme Doran; Jean-Charles Gautier; Heidrun Ellinger-Ziegelbauer; David Jackson; Tatiana Sharapova; Peter S T Yuen; Rachel J Church; Philippe Couttet; Roland Froetschl; James McDuffie; Victor Martinez; Parimal Pande; Lauren Peel; Conor Rafferty; Frank J Simutis; Alison H Harrill
Journal:  Crit Rev Toxicol       Date:  2021-05-26       Impact factor: 6.184

Review 8.  MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction.

Authors:  Solenne Paiva; Onnik Agbulut
Journal:  Front Cardiovasc Med       Date:  2017-11-20

9.  Bias in recent miRBase annotations potentially associated with RNA quality issues.

Authors:  Nicole Ludwig; Meike Becker; Timo Schumann; Timo Speer; Tobias Fehlmann; Andreas Keller; Eckart Meese
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

10.  Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples.

Authors:  Giuseppina E Grieco; Guido Sebastiani; Daniela Fignani; Noemi Brusco; Laura Nigi; Caterina Formichi; Giada Licata; Marco Bruttini; Romina D'Aurizio; Chantal Mathieu; Conny Gysemans; Francesco Dotta
Journal:  STAR Protoc       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.